Continuous hyperthermic peritoneal perfusion (CHPP) with anticancer agent in warm saline was performed in 9 patients with peritoneal dissemination and local-advanced intraabdominal malignancy following resection of primary or metastatic lesions. Immediately after excision of tumor and lymphadenectomy, CHPP was performed using saline containing 16 μg/ml of mitomycin-C (MMC) and 1500 μg/ml of 5-Flurouracil (5Fu) and warm at the temperature of 42 to 43 °C for 60 minutes. Five patients are cases of colo-rectal cancer with cancerous peritonitis. Two patients are cases of local advanced rectal cancer, who received CHPP for the purpose of prevention local recurrence of malignancy. One patient is a case of pancreatic cancer with cancerous peritonitis who received twice CHPP. The last one is a case of recurrent gastric cancer with cancerous peritonitis. He is the only one patient expired after CHPP. There is no immediate postoperative complication in these cases. Only transient change of liver function, WBC count, and albumin level were noted. CHPP treatment is a safe method in eradicating cancer cells in peritoneal dissemination or local advanced condition.
|Number of pages
|Biomedical Engineering - Applications, Basis and Communications
|Published - Jan 1 1994
ASJC Scopus subject areas